ClinicalTrials.gg
Active, not recruitingNCT07290569EVERLAST-BUpdated Nov 6, 2026

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

A Phase 2 interventional study of ORKA-001 and Placebo in Plaque Psoriasis, sponsored by Oruka Therapeutics, Inc.. Active, not recruiting at 36 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Oruka Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Updated Nov 6, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Planned enrollment
235th of 673
160 · median 77
Started
2025
with 24 others
Phase 2
200 of 764
5 open now
Primary completion
2026-10
later than 25 of 85 live
Registered
746th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 235th largest by planned enrollment of the 673 interventional ones that give a count, is one of 25 that started in 2025, is one of 200 in phase 2, reaches primary completion later than 25 of the 85 other live ones, and was the 746th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Read the detailed description

This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.

The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.

The study will consist of 4 periods:

  • Screening Period of up to 6 weeks
  • Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
  • Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
  • Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.
03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Phase 2
  • ORKA-001
  • Plaque psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants ≥ 18 years of age
  2. Have a diagnosis of plaque psoriasis for > 6 months
  3. Have moderate-to-severe chronic plaque psoriasis defined as:

    1. BSA ≥ 10%, and
    2. PASI ≥ 12, and
    3. IGA score of ≥ 3 on a 5-point scale
  4. Candidate for systemic therapy or phototherapy
  5. Women of must have a negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
  2. Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
  3. History of , except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
  4. A known to any components of the ORKA-001 drug product
  5. Women who are breastfeeding or plan to breastfeed during the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    (Induction Period - Arm 1) ORKA-001

    Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen.

    Drug: ORKA-001

  • Experimental
    (Induction Period - Arm 2) ORKA-001

    Participants will receive 300 mg ORKA-001 per protocol Induction regimen.

    Drug: ORKA-001

  • Experimental
    (Induction Period - Arm 3) ORKA-001

    Participants will receive 600 mg ORKA-001 per protocol Induction regimen.

    Drug: ORKA-001

  • Placebo comparator
    (Induction Period - Arm 4) Placebo

    Participants will receive Placebo per protocol Induction regimen.

    Other: Placebo

  • Experimental
    (Maintenance Period - Arm 1) ORKA-001

    Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

    Drug: ORKA-001

  • Experimental
    (Maintenance Period - Arm 2) ORKA-001

    Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

    Drug: ORKA-001

  • Placebo comparator
    (Maintenance Period - Arm 3) Placebo

    Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response.

    Other: Placebo

Interventions

  • ORKA-001 administered by subcutaneous (SC) injection

  • OtherPlacebo

    Placebo administered by subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16

    The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Week 16

Secondary outcomes

  1. Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16

    The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 16

  2. Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16

    Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Week 16

  3. Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16

    The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 16

  4. Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100

    The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Week 100

  5. Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100

    The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 100

  6. Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100

    The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Week 100

  7. Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100

    The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 100

  8. Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100

    The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

    Time frame: Week 100

  9. Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)

    Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms

    Time frame: Day 1 through Week 100

07

Study locations

36 sites
  • Oruka Therapeutics Investigative Site
    Phoenix, Arizona 85032, United States
  • Oruka Therapeutics Investigative Site
    North Little Rock, Arkansas 72117, United States
  • Oruka Therapeutics Investigative Site
    Los Angeles, California 90024, United States
  • Oruka Therapeutics Investigative Site
    Los Angeles, California 90045, United States
  • Oruka Therapeutics Investigative Site
    San Diego, California 92123, United States
  • Oruka Therapeutics Investigative Site
    Miami, Florida 33126, United States
  • Oruka Therapeutics Investigative Site
    Rolling Meadows, Illinois 60008, United States
  • Oruka Therapeutics Investigative Site
    Plainfield, Indiana 46168, United States
  • Oruka Therapeutics Investigative Site
    Rockville, Maryland 20850, United States
  • Oruka Therapeutics Investigative Site
    Kew Gardens, New York 11415, United States
  • Oruka Therapeutics Investigative Site
    Chapel Hill, North Carolina 27516, United States
  • Oruka Therapeutics Investigative Site
    Cleveland, Ohio 44106, United States
  • Oruka Therapeutics Investigative Site
    Mason, Ohio 45040, United States
  • Oruka Therapeutics Investigative Site
    Portland, Oregon 97201, United States
  • Oruka Therapeutics Investigative Site
    Portland, Oregon 97210, United States
  • Oruka Therapeutics Investigative Site
    Philadelphia, Pennsylvania 19104, United States
  • Oruka Therapeutics Investigative Site
    Frisco, Texas 75033, United States
  • Oruka Therapeutics Investigative Site
    Houston, Texas 77004, United States
  • Oruka Therapeutics Investigative Site
    Webster, Texas 77598, United States
  • Oruka Therapeutics Investigative Site
    Norfolk, Virginia 23502, United States
  • Oruka Therapeutics Investigative Site
    Surrey, British Columbia V3R 6A7, Canada
  • Oruka Therapeutics Investigative Site
    Surrey, British Columbia V3V 0C6, Canada
  • Oruka Therapeutics Investigative Site
    Fredericton, New Brunswick E3B 1G9, Canada
  • Oruka Therapeutics Investigative Site
    Ajax, Ontario L1S 7K8, Canada
  • Oruka Therapeutics Investigative Site
    Markham, Ontario L3P 1X3, Canada
  • Oruka Therapeutics Investigative Site
    Peterborough, Ontario K9J 5K2, Canada
  • Oruka Therapeutics Investigative Site
    Montreal, Quebec HZX 2V1, Canada
  • Oruka Therapeutics Investigative Site
    Québec, Quebec G1V 4X7, Canada
  • Oruka Therapeutics Investigative Site
    Heidelberg, Baden-Wuerrtemberg 69120, Germany
  • Oruka Therapeutics Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Oruka Therapeutics Investigative Site
    Bad Bentheim, Lower Saxony 48455, Germany
  • Oruka Therapeutics Investigative Site
    Kiel, Schleswig-Holstein 24105, Germany
  • Oruka Therapeutics Investigative Site
    Badalona, Barcelona 08916, Spain
  • Oruka Therapeutics Investigative Site
    Barcelona, Barcelona 08041, Spain
  • Oruka Therapeutics Investigative Site
    Madrid, Madrid 28002, Spain
  • Oruka Therapeutics Investigative Site
    Madrid, Madrid 28046, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Oct 2026, 10 months.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 10 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2027 → Oct 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 18, 2025
StartActual
Dec 3, 2025
Primary completionActual
Oct 21, 2026was Jun 2027
CompletionEst.
Dec 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2027→Oct 21, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Jun 2027→Oct 21, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07290569
Lead sponsor
Oruka Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Dec 3, 2025
Primary completion
Oct 21, 2026
Completion
Dec 2028 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avrukibart

Start the discussion